Darren Cunningham tells us the story behind Inflection Biosciences (and its name), the rationale of focusing on small molecule cancer treatments, his thoughts on the Irish biotech start-up scene, and his hopes for the company’s future development.
Can you first provide an introduction to Inflection Biosciences to our international audience?
"The Irish biotech and pharma sector has long had a strong and positive relationship with the pharma sector in the US, and I think we can continue to study the success of the indigenous US sector in mapping out our future for indigenous biotech"
